Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > LATEST
LATEST
-
BUSINESS Cell Resources Launches Umbilical Cord- and Amnion-Derived MSCs
July 15, 2026
-
BUSINESS iPark Eyes Shared AI Platform to Keep Japan in Global Drug Discovery Race
July 14, 2026
-
REGULATORY Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
-
REGULATORY CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
-
BUSINESS FDA Greenlights Leqembi Iqlik for Alzheimer’s Initiation Therapy
July 14, 2026
-
BUSINESS Santen, Kyorin Strike Co-Promotion Deal for Alesion Eyelid Cream
July 14, 2026
-
BUSINESS Takeda Commits Up to US$30 Million to Indonesia Plasma Partnership
July 14, 2026
-
BUSINESS Padcev/Keytruda Bags Expanded US Nod in Perioperative MIBC
July 14, 2026
-
BUSINESS Olumiant Oral Suspension Now Available in Japan: Lilly/Incyte
July 14, 2026
-
REGULATORY MHLW Urges Stakeholders to Define Essential LLP Information
July 14, 2026
-
COMMENTARY A Turning Point for Pharma? Chuikyo Reform Could Open Door to Greater Industry Role
July 13, 2026
-
REGULATORY Japan to Set Up Subgroup to Flesh Out Pharma Investment Roadmap: PM
July 13, 2026
-
BUSINESS Japan Pharma Market Grows 3.8% in FY2025 as Protected Brands Shine: IQVIA
July 13, 2026
-
REGULATORY Immunization Act Revision Faces Uncertain Fate as Diet Clock Ticks Down
July 13, 2026
-
REGULATORY MHLW Panel Examines Indication Mapping for OTC-Like Drug Charge Scheme
July 13, 2026
-
REGULATORY Japan Targets Drug Discovery, Policing in Vertical AI Push
July 13, 2026
-
BUSINESS Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
-
BUSINESS Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
-
ORGANIZATION FIRM Backs Growth Roadmap, Expects Better Investment Climate
July 10, 2026
-
ORGANIZATION JPMA Sees Honebuto Shifting toward Industry Promotion, Still Against Off-Year Cuts
July 10, 2026
ページ
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…